Novo Nordisk and Eli Lilly are battling for dominance in one of medicine’s largest and fastest-growing markets: drugs for obesity and weight loss.
On Monday, Novo announced encouraging results for its experimental drug CagriSema. In a Phase 3 study of patients with type 2 diabetes, CagriSema produced 12.4% average weight loss after 60 weeks, compared with 9.1% for Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity.
Stay informed.Stay ahead.
Join Washington Examiner for unlimited access to the news, analysis, and commentary that matter most.
See Options
Already a member? Log in
Already a print subscriber? Click here to login/register your account
